Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Omega-3s and cancer

This article was originally published in The Tan Sheet

Executive Summary

"Dietary supplementation with omega-3 fatty acids is unlikely to prevent cancer," Catherine MacLean, MD/PhD, RAND Health, et al., conclude in the Jan. 25 Journal of the American Medical Association. The authors analyzed 38 articles in 20 different cohorts identified through a database search. Among the 65 estimates of association between omega-3s and cancer identified across the cohorts, only 10 are statistically significant, the authors state. Significant associations between omega-3 fatty acid consumption and cancer risk were reported for breast, colorectal, lung, prostate and skin cancers. However, there were significant associations for both increased risk and decreased risk and "far more estimates that did not demonstrate any association," MacLean et al. state. Omega-3 consumption "varied a great deal" across the studies, but "basically no effect was found in any of the cohorts," the authors state. "This difference could be regarded as evidence that omega-3 fatty acids have no effect regardless of intake"...

You may also be interested in...



Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California

US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.

Topics

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel